Nonalcoholic steatohepatitis (NASH) is on track to become the leading contributor to the global burden of liver disease, in particular due to the finding that NASH is one of the commonest precursors of hepatocellular carcinoma (HCC) [1]. For example in the USA, while the percentage of total liver transplants for recipients with hepatitis C has decreased from 35.3 to 23.6%, the percentage of liver transplants for NASH has increased [2]. Retrospective reviews of two large biopsy databases reported that up to 5% of HCV patients also had NASH [3] and up to one-third of individuals with chronic HCV have type 2 diabetes, which has been associated with worsening outcomes of HCV infection [4].

In this issue of *Digestive Diseases and Sciences*, Bennhamou and colleagues evaluated the effects of NAFLD risk factors including obesity and diabetes on the long-term outcomes of patients with HCV treated with direct-acting antivirals (DAAs) [5]. The authors conducted a retrospective study of 33,003 DAA treated US Veterans between 2013 and 2015. The patients were categorized using the body mass index (BMI); diabetes was identified using ICD 9/10 codes in association with hemoglobin A1c > 6.5% or having an active prescription for diabetes medications. Patients were evaluated for the development of cirrhosis, liver decompensation, or the development of HCC and death with a mean follow-up of 3 years. They found an association between the presence of diabetes and increased mortality and liver-related adverse outcomes including HCC, even among patients without baseline cirrhosis. Patients who were obese also exhibited a higher risk of developing cirrhosis compared with normal-weight patients although surprisingly they had a lower risk of mortality and of developing HCC.

These results underscore the importance of diabetes as an independent risk factor for liver disease, and in particular, HCC development. In contrast to prior experiences with IFN-based treatments, the presence of insulin resistance or type 2 diabetes mellitus did not appear to diminish the rate of sustained virological response (SVR) to DAA treatments [6]. Conversely, while several early studies had suggested that DAA-associated SVR improves the metabolic status, two of those studies did not observe long-term glycemic control [7]. Though the current study did not examine if DAA treatment changed insulin resistance, these data are unlikely to be available in an administrative retrospective study, especially since insulin resistance is not measured in routine clinical practice. Future prospective studies should evaluate this potential association between DAA-associated SVR, changes in insulin resistance, and liver outcomes.

It is particularly worrisome that a significant number of patients with pre-existing diabetes developed HCC within a 3-year follow-up period (hazard ratio of 1.4). Generally, HCC develops on a background of cirrhosis or advanced fibrosis; in particular, the risk of HCC development among those who achieve HCV SVR and who do not have cirrhosis or advanced fibrosis is low [8]. This report suggests otherwise; that this is not necessarily the case for individuals with concomitant diabetes, and is consistent with a prior meta-analysis of 25 studies which showed that those with type 2 diabetes mellitus have an increased risk of HCC, even in the absence of pre-existing cirrhosis [9]. Since NAFLD is common among those with T2DM [9], one could speculate that the majority of those with pre-existing diabetes have concomitant NAFLD. Nevertheless, without the availability of histological data, it is unclear if those who subsequently
developed HCC had concomitant NASH, and if they had early or advanced liver fibrosis. These data are clinically relevant since they beg the question of whether individuals who achieved HCV SVR without liver cirrhosis should continue to be monitored or undergo HCC surveillance. Future multicenter studies will be needed in order to address this question, and perhaps identify those with diabetes most likely to develop HCC.

This study reinforces the limitations of using BMI to stratify metabolic and liver disease risks, and is consistent with the current WHO definition of the metabolic syndrome where obesity is defined by the presence of truncal obesity [10]. Patients with a high BMI may include those without sarcopenia; furthermore, the presence of ascites also increases body weight. Therefore, individuals with sarcopenia could have a normal BMI. Although the waist and hip circumference measurements are currently not routinely recorded in most routine practice settings, it would be important to evaluate if they are associated with HCC development and/or overall mortality. Perhaps the most promising method of simultaneously, objectively, and noninvasively assessing sarcopenia, visceral obesity, and liver morphology is the non-contrast abdominal CT scan, that has become an effective tool in this regard [11].

Despite the short follow-up, this study adds to the current literature, highlighting the contribution of metabolic risk factors such as T2DM as key drivers of chronic liver disease, including NAFLD and HCC. Given the rising NAFLD burden in the USA, providers should be cognizant of concomitant NAFLD risk factors and the potential risk of ongoing NAFLD-associated liver disease progression in those who achieve HCV SVR.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Compliance with Ethical Standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

**References**

1. Baffy G, Brunt EM, Caldwell S. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. *J. Hepatol.* 2012. https://doi.org/10.1016/j.jhep.2011.10.027.

2. Parrish NF, Feurer ID, Matsuoka LK, et al. The changing face of liver transplantation in the United States: the effect of HCV antiviral eras on transplantation trends and outcomes. *Transplant Direct* 2019. https://doi.org/10.1097/TXD.0000000000000866.

3. Brunt EM, Ramakrishnani S, Cordes BG, et al. Concordance of histologic features of steatohepatitis with other forms of chronic liver disease. *Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc.* 2003. https://doi.org/10.1097/01.mp.0000042420.21088.c7.

4. Hammerstad SS, Grock SF, Lee HJ, et al. Diabetes and hepatocellular carcinoma: a two-way association. *Front Endocrinol* 2015. https://doi.org/10.3389/fendo.2015.00134.

5. Benhammou JN, Moon AM, Pasigna JR, et al. Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C. *Dig Dis Sci.* (Epub ahead of print). https://doi.org/10.1007/s10620-020-06457-2.

6. Adinolfi LE, Rinaldi L, Marrone A, et al. The effect of sustained virologic response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C. *Expert Rev. Anti Infect. Ther.* 2018;16:595–597. https://doi.org/10.1080/14787210.2018.1505590.

7. Ribaldone DG, Sacco M, Saracco GM. The effect of viral clearance achieved by direct-acting antiviral agents on hepatitis C virus positive patients with type 2 diabetes mellitus: a word of caution after the initial enthusiasm. *J Clin Med* 2020. https://doi.org/10.3390/jcm9020563.

8. Ioannou GN, PaK Green, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. *J. Hepatol.* 2017. https://doi.org/10.1016/j.jhep.2017.08.030.

9. Williamson RM, Price JF, Glancy S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. *Diabetes Care.* 2011. https://doi.org/10.2337/dc10-2229.

10. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation - Alberti - 1998 - Diabetic Medicine - Wiley Online Library. https://onlinelibrary.wiley.com/doi/abs/10.1002%28SICI%291096-9136%28199807%2915%3A7%3C539%3A%3AAID-DIA668%3E3.0.CO%3B2-S. Accessed 31 Jul 2020.

11. Ronald J, Bozdogan E, Zaki IH, et al. Relative Sarcopenia with excess adiposity predicts survival after transjugular intrahepatic portosystemic shunt creation. *AJR Am. J. Roentgenol.* 2020. https://doi.org/10.2214/AJR.19.21655.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.